Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel

A panel of European experts in breast cancer and bone health convened in a face to face meeting to discuss the available evidence and draft guidance on how bisphosphonates should be used, in addition to standard adjuvant therapy, in early breast cancer. Our manuscript provides a thorough review of the clinical randomised trial evidence evaluating the use of bisphosphonates to a) prevent cancer therapy induced bone loss and b) prevent metastases and improve cancer outcomes. We detail and summarise recommendations to aid clinicians on the use of adjuvant bisphosphonates in this context.

from Cancer via ola Kala on Inoreader http://ift.tt/1IYThji
via IFTTT